Physician profile
Thomas Horn
NPI 1841516598
$14,803.11
in general payments reported to CMS, 2019-2025
13 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $313 · 2021: $521 · 2022: $326 · 2023: $390 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Consulting Fee: $1,620 · Travel and Lodging: $747 · Food and Beverage: $690 · Education: $5.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,440.00 |
| Consulting Fee | $1,620.00 |
| Travel and Lodging | $747.07 |
| Food and Beverage | $689.54 |
| Education | $5.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13,313.81 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $898.32 | 2019-2022 | |
| Abbvie INC. | $240.39 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $101.09 | 2019-2023 | Invega Sustenna |
| Alkermes, INC. | $65.46 | 2022-2023 | Aristada, Aristada Initio |
| Vanda Pharmaceuticals INC. | $41.89 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $30.36 | 2019-2023 | Abilify Maintena, Rexulti |
| Supernus Pharmaceuticals, INC. | $23.74 | 2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $20.71 | 2023 | Trintellix |
| Neurocrine Biosciences, INC. | $19.13 | 2022 | |
| Avanir Pharmaceuticals, INC. | $18.73 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.12 | 2023 | Quviviq |
| Acadia Pharmaceuticals INC | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.